Aprea Therapeutics Inc. (NASDAQ:APRE) saw an upside of 1.48% to close Monday at $5.47 after adding $0.08 on the day. The 5-day average trading volume is 1,538,140 shares of the company’s common stock. It has gained $5.67 in the past week. An average of 2,928,750 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,554,458.
APRE’s 1-month performance is 19.17% or $0.88 on its low of $4.32 reached on 09/23/21. The company’s shares have touched a 52-week low of $3.17 and high of $30.99, with the stock’s rally to the 52-week high happening on 02/11/21. YTD, APRE has achieved 11.18% or $0.55. However, the current price is down -82.35%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Oct 01, 11 days have gone by since the last insider trading activity for Aprea Therapeutics Inc. (APRE). Korbel Gregory Alan (SVP, Chief Business Officer) most recently sold 27,500 shares at $4.89 per share on Oct 01. This transaction cost the insider $134,475. SVP, Chief Scientific Officer, Abrahmsen Lars B., sold 50,000 shares at a price of $4.89 on Oct 01. Then, on Sep 20, SVP, Chief Scientific Officer Abrahmsen Lars B. sold 25,000 shares at a price of $4.97 per share. This transaction amounted to $124,250.
Aprea Therapeutics Inc. (APRE) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.APRE stock has a beta of 0.00. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 1.90.
Aprea Therapeutics Inc.’s quick ratio for the period ended June 29 was 6.70, with the current ratio over the same period at 6.70 meaning that APRE stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at -$0.22 million against revenue of $52.81 million.
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected APRE to announce -$0.47 per share in earnings in its latest quarter, but it posted -$0.48, representing a -2.10% surprise. EBITDA for the quarter stood at more than -$9.94 million. APRE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 10.6 million, with total debt at $0.2 million. Shareholders hold equity totaling $21.19 million
Let’s look briefly at Aprea Therapeutics Inc. (APRE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 68.62% to suggest the stock is trending Neutral, with historical volatility in this time period at 50.37%.
The stock’s 5-day moving average is $5.22, reflecting a +3.40% or $0.18 change from its current price. APRE is currently trading +24.32% above its 20-day SMA, +27.80% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +29.31% and -78.29% respectively.
Stochastic %K and %D was 77.46% and 68.16% and the average true range (ATR) pointed at 0.41. The RSI (14) points at 65.19%, while the 14-day stochastic is at 85.19% with the period’s ATR at 0.39. The stock’s 9-day MACD Oscillator is pointing at 0.17 and 0.35 on the 14-day charts.
In the most recent analyst report for Aprea Therapeutics Inc. (NASDAQ: APRE), Robert W. Baird downgraded it to a Neutral rating. They previously had an Outperform rating on the stock. Analysts offering their rating for APRE stock have a consensus rating for the stock as Underweight. Currently, 2 brokerage advisors rate APRE as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is APRE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.00 and a high of $5.00, with their median price target at $4.00. Looking at these predictions, the average price target given by analysts is for Aprea Therapeutics Inc. (APRE) stock is $4.00.